StandardX, a UK-based deep technology company developing advanced isotope production systems, has raised £10 million in seed funding led by Vsquared Ventures and East X Ventures. Additional investors include firstminute capital, UK Innovation and Science Seed Fund (UKI2S), Brevan Howard Macro Venture, and Geometry. The financing will support the development of what StandardX describes as the world’s first scalable isotope refinery, initially focused on producing rare materials for cancer diagnostics and treatment before expanding into fusion energy applications.
Founded in 2025 by nuclear engineers Richard Pearson and Ross Allen, StandardX is developing a proprietary accelerator-based system designed to manufacture multiple isotopes using a standardized industrial platform.
Isotopes are essential to several areas of healthcare, including medical imaging and radiopharmaceutical treatments. They also have applications in advanced energy systems, scientific research, and industrial processes.
However, global isotope production remains concentrated among a relatively small number of aging facilities and specialized machines. This limited infrastructure creates supply constraints that can delay research and complicate the development of new medical treatments.
StandardX aims to address these limitations by building a refinery capable of manufacturing a broad portfolio of isotopes at commercial scale. Unlike conventional production systems designed around individual isotopes, its technology is intended to support more flexible manufacturing.
The company envisions a distributed production network, with facilities located closer to customers to reduce dependence on geographically concentrated supply chains.
Its initial focus will be on medical isotopes used in cancer diagnosis and treatment, including materials needed for emerging targeted alpha therapies. These treatments are designed to deliver radiation directly to cancer cells while limiting damage to surrounding healthy tissue.
StandardX expects to deliver its first isotopes to a medical research partner in 2027, with industrial-scale production planned from 2029.
The financing will also support the establishment of the company’s first industrial site in London, where it plans to deploy its initial accelerator-based refinery system.
Beyond healthcare, StandardX intends to apply its technology to the production of tritium, a critical fuel used in certain fusion energy systems.
According to the company, the world’s available tritium inventory is estimated at approximately 25 kilograms, while a single commercial fusion power plant could require tens of kilograms annually.
StandardX has already signed agreements with fusion developers to manufacture tritium as they advance their technologies toward commercial deployment.
The company’s strategy is to establish a commercial isotope business serving existing medical demand while developing manufacturing capabilities that could eventually support the fusion energy industry.
StandardX currently has 15 scientists, engineers, and operators, with experience spanning SpaceX, The London Clinic, Oxford University, Cambridge University, Fermilab, and the UK Atomic Energy Authority. The new financing will support additional hiring, engineering, and production development.
KEY QUOTES:
“Isotopes underpin the next era of innovation across several key sectors, but all share the same constraints around supply. Shortages are most acute in cancer medicine, already impacting patients today, and stalling progress in the development of next-generation treatments. This problem will only get worse, with new cancer cases projected to increase 67% by 2050. So we’re building the platform the world needs to address this.”
Richard Pearson, Co-Founder and CEO of StandardX
“StandardX began with a problem: isotope supply limited by legacy infrastructure. This raise moves us from concept into engineering, physics into hardware, and conversations into delivery. Our immediate priority is our industrial site in London, where we will deploy our first isotope refinery system and work closely with clinicians and researchers to start building a reliable supply chain.”
Ross Allen, Co-Founder and CTO of StandardX
“Radiopharma is approaching an extraordinary inflection point, but isotope supply simply hasn’t kept pace. StandardX is building a fundamentally flexible production platform that can move with the science, from the isotopes medicine needs today to those that will define the next generation of cancer treatment.”
Lise Rechsteiner, General Partner at Vsquared Ventures
“StandardX is tackling a supply problem that matters enormously today in medicine, while building a platform that could become critical infrastructure for fusion tomorrow.”
Theodore Mollinger, General Partner at East X Ventures
